Link Discovered Between BRCA1 Protein and Aggressive Pediatric Cancer
Dr. Alexander Bishop and a team from the Greehey Children's Cancer Research Institute at UT Health San Antonio discovered a surprising connection between a breast cancer protein, BRCA1, and a pediatric cancer called Ewing sarcoma. Credit: UT Health San Antonio
Scientists with the Greehey Children's Cancer Research Institute at UT Health San Antonio have discovered a surprising connection between a breast cancer protein, BRCA1, and a pediatric cancer called Ewing sarcoma.
Their findings, reported March 7 in the journal Nature, reveal a completely new mechanism by which BRCA1 can be rendered dysfunctional. "The observations raise many new questions about both Ewing sarcoma and BRCA1 biology," said the study's senior author, Alexander J.R. Bishop, D.Phil., of UT Health San Antonio.
Ewing sarcoma is a pediatric bone and soft tissue cancer. The median age of Ewing sarcoma patients is 15 years, and more than half of patients are adolescents. "Our team worked to identify why Ewing sarcoma is usually sensitive to standard cancer drugs, with the hope of finding new targets for therapy and revealing new ways to treat the disease if it returns or does not respond to standard therapies," Dr. Bishop said.
Almost all Ewing sarcomas are caused by a rearrangement of two genes that are fused together. The resulting combination of the Ewing sarcoma protein, EWSR1, and another protein, usually FLI1, is called a "fusion oncogene." This bad actor promotes cancer.
The researchers reported in Nature that:
1. The mutant protein produced by the fusion oncogene interferes with normal EWSR1 protein function. Because of this, the cancer's normal cell functions run unchecked.
2. BRCA1, which repairs damaged DNA (genetic material) when those same cell functions shut off, cannot do this repair because the machinery keeps running.
"EWSR1 is like a train conductor who sees damage on the tracks ahead and stops the train," Dr. Bishop said. "BRCA1 is the repair crew who are passengers on the train and go fix the damage when the train stops. But now you've got this mutant bully, this fusion oncogene, who prevents the conductor from being able to stop the train and prevents the repair crew from getting off to work on the tracks."
This article has been republished from materials provided by UT Health San Antonio. Note: material may have been edited for length and content. For further information, please contact the cited source.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE